Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

This study tests whether combining osimertinib (a lung cancer targeted therapy) with dalpiciclib (a CDK4/6 inhibitor) can help people with advanced lung cancer whose cancer has a specific EGFR mutation and also has a CDK4/6 pathway abnormality that may cause resistance to standard treatment. **You may be eligible if...** - You have advanced non-small cell lung cancer with an EGFR mutation - Your cancer stopped responding to a third-generation EGFR-targeted drug - Your cancer has an abnormality in the CDK4/6 pathway - You have measurable cancer visible on scans - You have adequate organ function - You have received at least one prior chemotherapy **You may NOT be eligible if...** - You have previously been treated with a CDK4/6 inhibitor - You have active, uncontrolled brain metastases or cancer spreading to the lining of the brain - You have significant unresolved side effects from prior treatment Talk to your doctor to see if this trial is right for you.